Suscribirse

Additional autoimmune diseases associated with type 1 diabetes in children and adolescents: A French single-center study from 2014 to 2021 - 30/06/22

Doi : 10.1016/j.arcped.2022.03.002 
Marie Burbaud a, Emeline Renard a, S. Jellimann a, A. Luc b, M. Di Patrizio a, T. Remen b, Carole Legagneur a,
a Department of pediatrics, Regional University Hospital of Nancy, Allée du Morvan, Vandoeuvre-Lès-Nancy 54511, France 
b MPI department, Methodology, data management and statistic Unit, Regional University Hospital of Nancy, Vandoeuvre-Lès-Nancy, France 

Corresponding author.

Abstract

Context

Patients with type 1 diabetes (T1D) are more likely to develop other autoimmune diseases than the general population.

Objectives

To describe additional autoimmunity in a cohort of children and adolescents with T1D, as well as to identify factors associated with the presence of additional autoantibodies (AABs) and of additional autoimmune diseases (AADs).

Setting

This was a single-center retrospective cohort study of 179 children and adolescents (median age: 9.1 years) diagnosed with T1D between 2014 and 2020 in a specialized center in France. Patients were screened for autoimmune thyroiditis and celiac disease at T1D diagnosis and once every 1–2 years during follow-up. Other AADs and their specific autoantibodies were screened for only if clinical or laboratory signs were present.

Results

At T1D diagnosis, 15.6% of participants presented with at least one type of AAB including antibodies specific to Hashimoto's disease (TPOAb and/or TGAb) and/or to celiac disease (tTGAb and/or EMAb). Only 2.8% of participants presented with an AAD as early as T1D diagnosis. The median follow-up was 37 months. The cumulative incidence of AABs and AADs at 2 years of follow-up was, respectively, 3.9% and 5.4%, and it doubled at 3 years of follow-up. Only one patient, also affected by Down syndrome, was diagnosed with 2 AADs. Hashimoto's disease was the most frequently diagnosed AAD, followed by celiac disease, both at an asymptomatic stage. Vitiligo and Graves’ disease were also diagnosed in this cohort but affected few patients. Children aged 6–12 years were more likely to present with an AAD at diabetes diagnosis (p = 0.043).

Conclusion

: The high prevalence and incidence of additional autoimmunity in children and adolescents with T1D justifies regular screening of AABs and AADs.

El texto completo de este artículo está disponible en PDF.

Keywords : Pediatrics, Type 1 diabetes, Multiple autoimmunity

Abbreviations : AAB, AAD, ADA, EMAb, GADA, IAA, IA2, ICA, IgA, ISPAD, MODY, T1D, TPOAb, TGAb, TRAKs, tTGAb, ZnT8, 21OHAb


Esquema


 Financial Disclosure: The authors have indicated they have no financial relationships relevant to this article to disclose.


© 2022  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 29 - N° 5

P. 381-387 - juillet 2022 Regresar al número
Artículo precedente Artículo precedente
  • Are clinical features and cardiac biomarkers at admission related to severity in pediatric acute myocarditis? : Clinical features and cardiac biomarkers in pediatric acute myocarditis
  • Fatma Akgül, Anıl Er, Emel Ulusoy, Aykut Çağlar, Gamze Vuran, Pınar Seven, Murat Muhtar Yılmazer, Hasan Ağın, Hurşit Apa
| Artículo siguiente Artículo siguiente
  • Prevalence of overweight, obesity, and early adiposity rebound in nursery school children in southeastern France
  • B. Roth, R. Reynaud, V. Nègre, S. Gentile, V. Pauly, O. Bernard

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.